Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States

The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.

  •   Table of Contents

Download Guidelines

Management of Infants Born to Women with HIV Infection

Long-Term Follow-Up of Infants Exposed to Antiretroviral Drugs

Last Updated: December 7, 2018; Last Reviewed: December 7, 2018

Panel's Recommendations for the Long-Term Follow-Up of Infants Exposed to Antiretroviral Drugs
Panel's Recommendations
  • Children with in utero or neonatal exposure to antiretroviral (ARV) drugs who develop significant organ system abnormalities of unknown etiology, particularly of the nervous system or heart, should be evaluated for potential mitochondrial dysfunction (CIII).
  • It is important that the long-term medical record of a child without HIV includes information about in utero and neonatal ARV exposure (BIII).
Rating of Recommendations: A = Strong; B = Moderate; C = Optional
Rating of Evidence: I = One or more randomized trials with clinical outcomes and/or validated laboratory endpoints; II = One or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; III = Expert opinion

Download Guidelines